Comparative effects of lipid-lowering therapies

Progress in Cardiovascular Diseases

Volumn 47, Issue 2, 2004, Pages 73-104

  Davidson, Michael H ^a,b   Toth, Peter P ^c,d  

^a RADIANT RESEARCH   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Sterling Rock Falls Clinic ^*  (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; ERYTHROMYCIN; EZETIMIBE; FELODIPINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NELFINAVIR; NICOTINIC ACID; NIFEDIPINE; NIFOLDIPINE; PAROXETINE; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ATHEROSCLEROSIS; CANCER; CARDIOVASCULAR RISK; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; INCIDENCE; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; PHYSIOLOGY; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL;

EID: 10044240704     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2004.04.007     Document Type: Article

References (210)

1. Istvan E. Statin inhibition of HMG-CoA reductase A 3-dimensional view. Atheroscler Suppl. 4:2003;3-8
2. McTaggart F., Buckett L., Davidson R., et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 87:2001;28B-32B
3. Faggiotto A., Paoletti R. Do pleiotropic effects of statins beyond lipid alternations exist in vivo? What are they and how do they differ between statins? Curr Atheroscler Rep. 2:2000;20-25
4. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins Implications for cardiovascular event reduction [review]. JAMA. 279:1998;1643-1650
5. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718
6. Gould K.L., Martucci J.P., Goldbert D.I., et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease A potential noninvasive marker of healing coronary endothelium. Circulation. 89:1994;1530-1538
7. Packard C.J., Shepherd J., Cobbe S.M., et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445
8. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B
9. Gotto AM Jr, Whitney E, Stein EA,, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101: 477-484
10. Yusuf S., Anand S. Cost of prevention. The case of lipid lowering [editorial; comment]. Circulation. 93:1996;1774-1776
11. Ballantyne C.M. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 82:(9A):1998;3Q-12Q
12. Buchwald H., Boen J.R., Nguyen P.A., et al. Plasma lipids and cardiovascular risk: A POSCH report. Program on the surgical control of the hyperlipidemias. Atherosclerosis. 154:2001;221-227
13. Agbin N.E., Brater C., Becker P.A., et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 64:1998;369-377
14. Spach D.H., Bauwens J.E., Clark C.D., et al. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 154:1991;213-215
15. Oserg K., Bauman J.L. QT interval prolongation and torsades de pointes due to erythromycin lactobioante. Pharmacotherapy. 15:1995;687-692
16. Kantola T., Kivisio K., Neuvonen P. Erythromycin and verapamil considerably increase simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 64:1998;177-182
17. Harris S., Hilligoss D.M., Colangelo P.M., et al. Azithromycin and terfenidine Lack of drug interaction. Clin Pharmacol Ther. 58:1995;310-315
18. Bottorff M.B., Behrens D.H., Gross A., et al. Differences in the metabolism of lovastatin and pravastatin as assessed by CYP 3A4 inhibition with erythromycin. Pharmacotherapy. 17:1997;184
19. Lees R.S., Lees A.M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 333:1995;664-665
20. Neuvonen P.J., Kantola T., Kivisio K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 63:1998;332-341
21. Miehalase E.L. Update Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 18:1998;84-112
22. Nemeroff C.B., DeVane L., Pollack B.G. New antidepressants and the cytochrome P450 system. Am J Psychiatry. 153:1996;311-320
23. Gruer P.J.K., Vega J.M., Mercuri M.F., et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 84:1999;811-815
24. Hollander A.M.J., van Rooij J., Lentjes E.G.W.M., et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 57:1995;318-324
25. Abramowicz M. Grapefruit juice interactions with drugs. Med Lett Drugs Ther. 37:1993;73-74
26. Kupferschmidt H.T., Riem H., Ziegler W.H., et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 58:1995;20-28
27. Edwards D.J., Bernier S.M. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. 39:1996;1025-1030
28. Fuhr U., Frummert A.L. The fate of naringin in humans A key to grapefruit juice-drug interactions. Clin Pharmacol Ther. 58:1995;365-373
29. Physicians' Desk Reference, 57th ed. Montvale, NJ, Medical Economics, 2003
30. Corpier C.L., Jones P.H., Suke W.N., et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 260:1988;239-241
31. Ayanizn J.Z., Ruchs C.L., Stone R.M. Lovastatin and rhabdomyolysis (letter). Ann Intern Med. 109:1988;682-683
32. Ragazzi M.B., Iacona I., Campana C., et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 25:1993;2732-2734
33. Olbricht C., Wanner C., Eisenhauer T., et al. Accumulation of lovastatin, but not pravastatin, in blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 62:1997;311-321
34. Boberg M., Angerbauer R., Fey P., et al. Metabolism of cerivastatin by human liver microsomes in vitro Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos. 25:1997;321-331
35. Barbir M., Rose M., Kushwaha S., et al. Low-dose simvastatin for the treatment of hypercholesterolemia in recipients of cardiac transplantation. Int J Cardiol. 33:1991;241-246
36. Vanhaecke J., Van Cleemput J., Van Lierde J., et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation. 58:1994;42-45
37. Pflugfelder P.W., Huff M., Oskalns R., et al. Cholesterol-lowering therapy after heart transplantation A 12-month randomized trial. J Heart Lung Transplant. 14:1995;613-622
38. Wassar C., Kreker-Goth A., Galla J. Use of HMG CoA reductase inhibitors after kidney and heart transplants. Bio Drugs. 8:1997;387-393
39. Christians U. Combination of pravastatin and cyclosporin in transplant patients. Clin Pharmacol Ther. 32:1997;173-174
40. Jardine A., Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients A review of clinical and safety experience. J Clin Pharm Ther. 24:1999;397-408
41. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients A multicentre, randomised, placebo-controlled trial. Lancet. 361:2003;2024-2031
42. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622
43. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009
44. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357
45. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) A randomised controlled trial. Lancet. 360:2002;1623-1630
46. Spence J.D., Munoz C.E., Hendricks L., et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 76:1995;80A-83A
47. Newman C.B., Palmer G., Silbershatz H., et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 92:2003;670-676
48. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) A multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
49. Colhoun H.M., Thomason M.J., Mackness M.I., et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med. 19:2002;201-211
50. Davidson M.H. Rosuvastatin A highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 11:2002;125-141
51. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 92:2003;152-160
52. Kannel W.B. High-density lipoproteins epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 52:1983;9B-12B
53. Stein E.A. Introduction Rosuvastatin - An efficacy assessment based on pooled trial data. Am J Cardiol. 91:2003;1C-2C
54. Crestor; rosuvastatin calcium: IPR (trade) 630100, IPR (sample) 630200, API (sample) 23073-0. Package insert. Wilmington, DE, AstraZeneca, 2003
55. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
56. Catapano A.L. Ezetimibe A selective inhibitor of cholesterol absorption. Eur Heart J Suppl. 3:2001;E6-E10
57. Davis H.R., Compton D.S., Hoos L., et al. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption [abstract P3500]. Eur Heart J. 21:(Suppl):2000;636
58. Knopp R.H., Bays H., Manion C.V., et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins [abstract P175]. Atherosclerosis. 2:(Suppl):2001;90
59. van Heek M., Farley C., Compton D.S., et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 129:2000;1748-1754
60. Zetia [prescribing information]. 2002;Merck/Schering-Plough Pharmaceuticals, North Wales, PA
61. Bays H.E., Moore P.B., Drehobl M.A., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia Pooled analysis of two phase II studies. Clin Ther. 23:2001;1209-1230
62. Punwani N, Pai S, Bach C,, et al. Effect of food on oral bioavailability of SCH58235 in healthy male volunteers [abstract]. AAPS Pharm Sci [serial online] 1(Suppl):S486
63. van Heek M., France C.F., Compton D.S., et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 283:1997;157-163
64. Rosenblum S.B., Huynh T., Alfonso A., et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S) -(4-hydroxyphenyl)-2-azetidinone (SCH58235) A designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem. 41:1998;973-980
65. van Heek M., Farley C., Compton D.S., et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 134:2001;409-417
66. van Heek M., Compton D.S., Davis H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol. 415:2001;79-84
67. Sudhop T., Lutjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 106:2002;1943-1948
68. Zhu Y., Statkevich P., Kosoglou T., et al. Effect of SCH 58235 on the activity of drug metabolizing enzymes in vivo (Abstract PIII-43). Clin Pharmacol Ther. 67:2000;152
69. Zhu Y., Statkevich P., Kosoglou T., et al. Lack of a pharmacokinetic interaction between ezetimibe and atorvastatin (Abstract PIII-15). Clin Pharmacol Ther. 69:2001;68
70. Kosoglou T., Meyer I., Veltri E.P., et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 54:2002;309-319
71. Reyderman L., Kosoglou T., Statkevich P., et al. No pharmacokinetic drug interaction between ezetimibe and lovastatin (Abstract PIII-8). Clin Pharmacol Ther. 69:2001;66
72. Reyderman L., Statkevich P., Kosoglou T., et al. No pharmacokinetic drug interaction between ezetimibe and either cerivastatin or fluvastatin. AAPS Pharm Sci [serial online]. 3:(Suppl):2001
73. Statkevich P., Reyderman L., Kosoglou T., et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide (Abstract PIII-12). Clin Pharmacol Ther. 69:2001;67
74. Kosoglou T., Statkevich P., Bauer K.S., et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin [abstract]. AAPS Pharm Sci[serial online]. 3:(Suppl):2001;3
75. Keung A.C., Kosoglou T., Statkevich P., et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives (Abstract PII-89). Clin Pharmacol Ther. 69:2001;55
76. Bauer K.S., Kosoglou T., Statkevich P., et al. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin (Abstract PI-15). Clin Pharmacol Ther. 69:2001;5
77. Kosoglou T., Guillaume M., Sun S., et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe (Abstract W6.1). Atherosclerosis. 2:(Suppl):2001;38
78. Krishna G., Kosoglou T., Ezzet F., et al. Effect of cimetidine on the pharmacokinetics of ezetimibe [abstract]. AAPS Pharm Sci [serial online]. 3:(Suppl):2001;9
79. Courtney R.D., Kosoglou T., Statkevich P., et al. Effect of antacid on the pharmacokinetics of ezetimibe. Clin Pharmacol Ther. 71:2002;80
80. Dujovne C.A., Ettinger M.P., McNeer J.F., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 90:2002;1092-1097
81. Knopp R.H., Gitter H., Truitt T., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 8:2003;729-741
82. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 40:2002;2125-2134
83. Ballantyne C., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia A prospective, randomized, double-blind trial. Circulation. 19:2003;e9043-e9044
84. Kerzner B., Corbelli J., Sharp S., et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 91:2003;418-424
85. Melani L., Mills R., Hassman D., et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia A prospective, randomized, double-blind trial. Eur Heart J. 8:2003;685-689
86. Gagné C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 90:2002;1084-1091
87. Tolleshaug H., Hobgood K.K., Brown M.S., et al. The LDL receptor locus in familial hypercholesterolemia Multiple mutations disrupt transport and processing of a membrane receptor. Cell. 32:1983;941-951
88. Glueck C.J., Spiers J., Tracy T., et al. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism. 40:1991;842-848
89. Castelli W.P., Garrison R.J., Wilson P.W.F., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels The Framingham Study. JAMA. 256:1986;2835-2838
90. Despres J.P., Lemieux I., Dagenais G.R., et al. HDL-cholesterol as a marker of coronary heart disease risk The Quebec cardiovascular study. Atherosclerosis. 153:2000;263-272
91. Austin M., Rodriguez B., McKnight B., et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American Men. Am J Cardiol. 86:2000;412-416
92. Goldbourt U., Medalie J. High-density lipoprotein cholesterol and incidence of coronary heart disease The Israeli ischemic heart disease study. Am J Epidemiol. 109:1979;296-308
93. Backer G., Bacquer D., Kornitzer M. Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis. 137:1998;S1-S6
94. Rywik S., Manolio T., Pajak A., et al. Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Am J Cardiol. 84:1999;540-548
95. Yu S., Yarnell J.W.G., Sweetnam P., et al. High density lipoprotein subfractions and the risk of coronary heart disease 9-years follow-up in the Caerphilly Study. Atherosclerosis. 166:2003;331-338
96. Miller N., Forde O., Thelle D., et al. High-density lipoprotein and coronary heart disease A prospective case-control study. Lancet. 1:1997;965-968
97. Assman G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary disease (the PROCAM experience). Am J Cardiol. 70:1992;733-737
98. Yarnell J.W., Patterson C.C., Sweetnam P.M., et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Arteroiscler Thromb Vasc Biol. 21:2001;1340-1345
99. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 86:(Suppl):2000;19L-22L
100. Burke A.P., Farb A., Malcom G.T., et al. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA. 281:1999;921-926
101. Koren-Morag N., Tanne D., Graff E., et al. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease. Arch Intern Med. 162:2002;993-999
102. Weverling-Rijinsburger A.W., Jonkers I.J., Exel E., et al. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med. 163:2003;1549-1554
103. Mathisesen E.B., Bonaa K.H., Joakimsen O. High-density lipoprotein cholesterol are associated with echolucent carotid artery plaques The Tromso study. Stroke. 32:2001;1960-1965
104. Shah P., Amin J. Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation. 85:1992;1279-1285
105. Pearson T.A., Bulkley B., Achuff S., et al. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol. 109:1979;285-295
106. Zuliani G., Romagnoni F., Bollini C., et al. Low levels of high-density lipoprotein cholesterol are a marker of disability in the elderly. Gerontology. 45:1999;317-322
107. Johnson C.L., Rifkind B.M., Sempos C.T., et al. Declining serum total cholesterol levels among US adults The National Health and Nutrition Examination Surveys. JAMA. 269:1993;3002-3008
108. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA. 287:2002;356-359
109. Genest J.J., McNamara J.R., Salem D.N., et al. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 67:1991;1185-1189
110. Rubins H.B., Robins S.J., Collins D., et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 75:1995;1196-1201
111. Exel E., de Craen A.J.M., Gussekloo J., et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 51:2002;716-721
112. Gordon D., Probstfield J., Garrison R., et al. High-density lipoprotein cholesterol and cardiovascular risk. Circulation. 79:1989;8-15
113. Toth P.P. High-density lipoprotein Epidemiology, metabolism, and antiatherogenic effects. Disease-a-Month. 47:2001;367-414
114. Toth P.P. Reverse cholesterol transport High-density lipoprotein's magnificent mile. Curr Atheroscler Rep. 5:2003;386-393
115. Eriksson M., Carlson L.A., Miettinen T.A., et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 100:1999;594-598
116. Badimon J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 85:1990;1234-1241
117. Badimon J., Fuster V., Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation. 86:1992;86-94
118. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA. 290:2003;2292-2300
119. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation. 101:2000;2510-2517
120. Stremler K.E., Stafforini D.M., Prescott S.M., et al. Human platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem. 266:1991;11095-11103
121. Nofer J.R., Levkaus B., Wolinska I., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 276:2001;34480-34485
122. Nofer J., Kegrel B., Fobker M., et al. HDL and arteriosclerosis Beyond reverse cholesterol transport. Atherosclerosis. 161:2002;1-16
123. Mineo C., Yuhanna I.S., Quon M.J., et al. High density lipoprotein-induced endothelial nitric oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 278:2003;9142-9149
124. Li X., Zhao S., Zhang S., et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol. 73:2000;231-236
125. Barter P. Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins. Clin Exp Pharmacol Physiol. 24:1997;286-287
126. Lusis A.J. Atherosclerosis. Nature. 407:2000;233-241
127. Aviram M., Brook G. Platelet interaction with high and low density lipoproteins. Atherosclerosis. 46:1983;259-268
128. Fleisher L., Tall A., Witte L., et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 257:1982;6653-6655
129. Griffin J., Kojima K., Banka C., et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 103:1999;219-227
130. Assman G., Cullen P., Schulte H. The Munster Heart Study (PROCAM) - Results of follow-up at 8 years. Eur Heart J. 19:1998;A2-A11
131. Jeppesen J., Hein H.O., Suadicani P., et al. Triglyceride concentration and ischemic heart disease - An eight-year follow-up in the Copenhagen Male study. Circulation. 97:1998;1029-1036
132. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level A meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:1996;213-219
133. Inoue T., Saniabadi A.R., Matsunaga R., et al. Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles. Atherosclerosis. 139:1998;363-367
134. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 86:2000;943-949
135. Assmann G. Pro and con High-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 87:(Suppl):2001;2B-7B
136. Reaven G.M. The pathophysiological consequences of adipose tissue insulin resistance. Reaven G.M., Laws A. Insulin Resistance The Metabolic Syndrome X. 1999;233-246 Humana Press, Totowa, NJ
137. Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458
138. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care. 26:(Suppl):2003;S83-S86
139. Turner R.C., Millns H., Neil H.A.W., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 316:1998;823-828
140. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 10:1999;245-267
141. Kersten S., Desvergne B., Wahil W. Roles of PPARs in health and disease. Nature. 405:2000;421-424
142. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148
143. Torra I.P., Gervois P., Stael S. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Lipidology. 10:1999;151-159
144. Chapman M.J. Fibrates in 2003 Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis. 171:2003;1-13
145. Staels B., Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis. 137:1998;S19-S23
146. Vu-Dac N., Schoonjans K., Laine B., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. Clin Invest. 96:1995;741-750
147. Bolibar I., von Eckardstein A., Assman G., et al. Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris. Thromb Haemost. 84:2000;955-960
148. Luc G., Bard J.M., Ferrieres J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease. The PRIME Study. Arterioscler Thromb Vasc Biol. 22:2002;1155-1161
149. Poulter N. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL target levels in 7098 patients with dyslipidemia. Br J Cardiol. 6:1999;682-685
150. Fruchart J.C. Peroxisome proliferator-activated receptor - A activation and high-density lipoprotein metabolism. Am J Cardiol. 88:(Suppl):2001;24N-29N
151. Libby P. Inflammation in atherosclerosis. Nature. 420:2002;868-874
152. Delerive P., De Bosscher K., Besnard S., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors. J Biol Chem. 274:1999;32048-32054
153. Delerive P., Martin-Nizard F., Chinetti G., et al. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway. Circ Res. 85:1999;394-402
154. Neve B.P., Fruchart J.C., Staels B. Role of the peroxisome proliferator-activated receptors (PPARs) in atherosclerosis. Biochem Pharmacol. 60:2000;1245-1250
155. Delerive P., Gervois P., Fruchart J.C., et al. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem. 275:2000;36703-36707
156. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 22:2002;1135-1143
157. Ridker P.M., Bassuk S.S., Toth P.P. C-Reactive protein and risk of cardiovascular disease Evidence and clinical application. Curr Atheroscler Rep. 5:2003;341-349
158. Wang T.D., Chen W.J., Lin J.W., et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia Relations with baseline lipid profiles. Atherosclerosis. 170:2003;315-323
159. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 273:1998;32833-32841
160. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and the decline in incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 260:1988;641-651
161. Robins S.J., Collins D., Wittes J.T., et al. VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA. 285:2001;1586-1589
162. Rubins H.B., Davenport J., Babikian V., et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. Circulation. 103:2001;2828-2833
163. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease. Arch Intern Med. 162:2002;2597-2604
164. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention Study. Circulation. 102:2000;21-27
165. Ericsson C.-G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853
166. Frick M.H., Syvänne M., Nieminen M.S., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 96:1997;2137-2143
167. Karpe F., Taskinen M.R., Nieminen M.S., et al. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis. 157:2001;181-187
168. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study: A randomised study. Lancet. 357:2001;905-910
169. The Lipids in Diabetes Study
170. Pauciullo P., Borgnino C., Paoletti R., et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with a mixed hyperlipidaemia (FACT study). Atherosclerosis. 150:2000;429-436
171. Athyros V.G., Papageorgiou A.A., Kontopoulos A.G. Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis. 155:2001;263-264
172. Backman J.T., Kyrklund C., Neuvonen M., et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmocol Ther. 72:2002;685-691
173. Prueksaritanont T., Zhao J.J., Ma B., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 301:2002;1042-1051
174. Kyrklund C., Backman J.T., Kivisto K.T., et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 69:2001;340-345
175. Kyrklund C., Backman J.T., Neuvonen M., et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 73:2003;538-544
176. Martin P.D., Dane A.L., Schneck D.W., et al. An open label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 25:2003;459-471
177. Pan W.J., Gustavson L.E., Achari R., et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 40:2000;316-323
178. Bissonnette R., Treacy E., Rozen R., et al. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis. 155:2001;455-462
179. Sakai T., Kamanna V.S., Kashyap. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 21:2001;1783-1789
180. Ganji S.H., Tavintharan S., Zhu D., et al. Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis. Arterioscler Thromb Vasc Biol. 22:2002;878
181. Ganji S.H., Kamanna V.S., Kashyup M.L. Niacin and cholesterol Role in cardiovascular disease (review). J Nutr Biochem. 14:2003;298-305
182. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 91:2003;1432-1436
183. Gray D.R., Morgan T., Chretien S.D., et al. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 121:1994;252-258
184. McKenney J.M., Proctor J.D., Harris S., et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 271:1994;672-677
185. Goldberg A., Alagona P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 85:2000;1100-1105
186. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan) A long-term study. Am J Cardiol. 82:1998;74U-81U
187. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 162:2002;1568-1576
188. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: A randomized trial. JAMA. 284:2000;1263-1270
189. Chesney C.M., Elam M.B., Herd A., et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J. 140:2000;631-636
190. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372
191. Garg R., Malinow M., Pettinger M., et al. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J. 138:1999;1082-1087
192. Knopp R.H., Ginsberg J., Albers J.J., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects Clues to mechanism of action of niacin. Metabolism. 34:1985;642-650
193. Zema M.J. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia A randomized, open-label, crossover study. J Am Coll Cardiol. 35:2000;640-646
194. Wolfe M.L., Vartanian S.F., Ross J.L., et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 87:2001;476-479
195. Guyton J.R., Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol. 82:1998;82U-84U
196. Schlierf G., Dorow E. Diurnal patterns of triglyceride, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest. 52:1973;732-740
197. Vogel R.A., Corretti M.C., Plotnick G.D. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol. 36:2000;1455-1460
198. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381
199. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients Long-term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255
200. Canner P.L., Furberg C.D., Terrin M.L., et al. Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome Results from the Coronary Drug Project. J Am Coll Cardiol. 39:2003;291A
201. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418
202. Blankenhorn D.H., Nessim S.A., Johnson R.L., et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240
203. Cashin-Hemphill L., Mack W.J., Pogada J.M., et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis A 4-yr follow-up. JAMA. 264:1990;3013-3017
204. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298
205. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592
206. Cheung M.C., Zhao X.Q., Chait A., et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 21:2001;1320-1326
207. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292:2001;1160-1164
208. Jones P., Kafonek S., Laurora I., et al. for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587
209. Jones P.H., Davidson M.H., Stein E.A., et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 92:2003;152-160
210. Stein E.A., Strutt K., Southworth H., et al. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 92:2003;1287-1293